Analysis
AI & Data
Adult acute leukaemia MRD: keep the molecular comparator in view
A marrow series in adults compared flow MRD with molecular MRD. The paired result is most interpretable when the disease, molecular target and treatment time point are preserved.
CFCM Technical Review. DOI 10.3390/cancers15205064.
Standfirst: A marrow series in adults compared flow MRD with molecular MRD. The paired result is most interpretable when the disease, molecular target and treatment time point are preserved.
Start with specimens and disease groups
Van der Linde and colleagues studied 134 consecutive bone marrow aspirates submitted for flow MRD testing at Westmead Hospital. The series included 47 B-ALL and 87 AML aspirates. These are specimen counts. Analyses of paired results and one-year trajectories use different subsets.

Why paired results can diverge
Flow identifies abnormal cellular phenotypes. Molecular tests follow a target selected for the disease and patient. In B-ALL, the study included immunoglobulin rearrangement testing, while AML comparisons included mutation or fusion targets where appropriate. A discordant result can therefore reflect target choice, sampling or assay sensitivity. The study showed variable concordance below 5% by flow in B-ALL, while indeterminate results were predominantly discordant.
Read the trajectory in context
The authors examined serial flow patterns and one-year outcomes separately for B-ALL and AML. The observations are useful for designing a discordance review, but the sizes of the trajectory groups, available targets and variation in treatment preclude a single rule for interpreting every paired result.
Daily Learning Pill
Before interpreting discordance, confirm the specimen time point, exact molecular target and the evaluable flow denominator.
Read the original article.